Replies to post #159087 on Biotech Values

[jbog]

Being that Sanofi and Biogen drug had ample time to evaluate the marketplace prior to approval their respective pricing could be anything but a coincidence.

BG-12's trial results coupled with its modest pricing premium puts it in a sweet spot.